2025-524299-44-00Not yet recruitingPhase 1
First study evaluating the safety and dosage of YG-01 in patients with a malignant brain tumor
Source: EU CTIS (euclinicaltrials.eu) · Last updated 29 Jun 2026
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- First submitted
- 5 Mar 2026
- Start date
- 1 Jun 2026
- Lead sponsor
- Ygion Biomedical GmbH
- Diseases
- Glioblastoma
- EU CT number
- 2025-524299-44-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 15
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with glioblastoma, a malignant brain tumor. It tests the safety and dose of YG-01.
- Age
- 18 years or older
- Sex
- Men and women can join.
Read by machine on 9 Nov 2026.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medical University of Vienna | Vienna | Austria | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.